Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOLANO: AZD8233 in Hyperlipidaemia
NCT04964557Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2021
- Primary completion
- Jul 2022
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in hyperlipidemia comparing AZD8233 with Placebo (2 arms). Primary endpoints: Percentage Change From Baseline on Serum LDL-C at Day 197 and Number of Subjects With Adverse Events at Day 281. Started Jul 2021; status: completed.
02
Drugs
AZD8233
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on NCT04964557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04964557.